Fluoxetine has an antiviral effect on COVID-19 patients partly because they are associated with decreased plasma levels of pro-inflammatory cytokines via the Sig-1R agonism (Fred et al., 2021). The gene discussed is SIGMAR1; the disease is COVID-19.